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A systematic review of the adult-onset, clinically-amyopathic dermatomyositis subphe-
notype: A Missing link within the spectrum of idiopathic inﬂammatory myopathies.
P Geraminejad, J Lewis, L Doughty, H W Walling, and R D Sontheimer.
Iowa City, Iowa; Kansas City, Kansas and Oklahoma City, Oklahoma.
Clinically-amyopathic DM (CADM) is an umbrella designation for individuals having either
amyopathic DM (ADM) (syn. DM sine´ myositis) [i.e., presence of the hallmark inflammatory
cutaneous manifestations of DM in individuals who display no muscle weakness and have
normal muscle enzymes for 6 months or longer] or hypomyopathic DM (HDM) [i.e., a des-
ignation for individuals who meet the criteria for ADM but who are found to have some
evidence of muscle inflammation on muscle testing but no muscle weakness]. To further
characterize the CADM subphenotype, we carried out a systematic review of the published
literature on the adult-onset CADM. We identified 301 adult-onset CADM cases (18 year or
older) reported from over 19 countries. The average duration of DM skin disease was 3.74
year (range: 6 months to420 year) and 73% were female. Among 37 patients with HDM that
were identified, the average duration of disease was 5.4 year and none had developed
muscle weakness at the time of their case reports. 14 of the reported CADM patients de-
veloped muscle weakness greater than 6 months after onset of their skin disease (15 months
to 6 year). Surprisingly, 45/301 (15%) of the adult-onset CADM cases identified developed at
times fatal interstitial lung disease (ILD). Our review also identified 6 published cases of
individuals having DM skin disease without muscle weakness who died from ILD less than 6
months after onset of their DM skin disease (i.e., ‘‘pre-myopathic DM’’). In addition, a tem-
porally associated internal malignancy was found in 42/301 (14%) of the identified adult-
onset CADM cases. A positive ANA was reported in 63% and myositis-specific autoanti-
bodies (e.g., Jo-1) in only 3.5% of the reported CADM patients in whom such data was
available. In conclusion, this systematic review has demonstrated that the incidence and
prevalence of adult-onset CADM is greater than previously thought. In addition, such patients
are at risk for developing the same potentially-fatal disease associations/complications ex-
perienced by CDM patients (e.g., ILD, internal malignancy, late-onset muscle weakness).
Systematic, population-based studies of the epidemiology and management of adult-onset
CADM are needed.
Children with eczema herpeticum during treatment with topical tacrolimus ointment and
pimecrolimus cream: a case series.
M L Curry, and K R Carder.
Dallas, Texas.
Eczema herpeticum is a potentially serious complication of atopic dermatitis and other forms
of eczema. Topical tacrolimus and pimecrolimus are newer immunosuppressive agents that
are effective treatments for atopic dermatitis. No causal relationship has been established
between eczema herpeticum and topical treatment with tacrolimus and/or pimecrolimus. A
few case reports describing eczema herpeticum in adults using topical tacrolimus ointment
have emphasized the need to be aware of the complication and to identify patients at risk. We
describe 15 consecutive cases of eczema herpeticum occurring between January, 2002 and
December, 2004 in children ages 5 months to 10 year of age. Ten of the 15 patients with
eczema herpeticum were using topical tacrolimus and/or pimecrolimus either alone or in
combination with topical steroids. Two patients using both topical steroids and pimecrolimus
developed eczema herpeticum on the areas treated with pimecrolimus exclusively, while the
areas treated with topical steroids were spared. One 8 month-old white male on topical
tacrolimus developed generalized eczema herpeticum and systemic levels of FK-506. Our
series demonstrates the need for more studies evaluating the potential risk of eczema her-
peticum in children using topical tacrolimus and/or pimecrolimus. In addition, it is important
to educate families and primary care physicians about eczema herpeticum in order to help
hasten diagnosis and treatment.
Differential expression of phosphorylated NF-kB/RelA in normal and psoriatic epidermis
and downregulation of NF-kB in response to treatment with etanercept.
P F Lizzul, A Aphale, R Malaviya, Y Sun, S Masud, V Dombrovskiy, and A B Gottlieb.
New Brunswick, New Jersey.
Etanercept, a recombinant human TNF receptor fusion protein, is FDA approved for psoriasis
and psoriatic arthritis. TNFa increases the synthesis of proinflammatory cytokines and leads
to the activation of multiple signaling pathways, including NF-kB. The Rel/NF-kB transcription
factors play a central role in numerous cellular processes, including the stress response and
keratinocyte proliferation and differentiation. Utilizing a phosphorylation specific antibody we
examined the expression of active nuclear NF-kB/RelA via immunohistochemistry in normal
skin, non-lesional psoriatic skin, lesional psoriatic skin and lesional skin from patients treated
with etanercept. There was no expression of active NF-kB in normal epidermis, whereas a
basal level of constitutive active phosphorylated NF-kB/RelA was present in uninvolved ep-
idermis from psoriasis patients. There was also significant upregulation of active phosphory-
lated NF-kB/RelA in epidermis from psoriatic plaques. Serial biopsies from psoriasis patients
treated with etanercept at 1 month, 3 month, and 6 months demonstrated a significant down
regulation of phosphorylated NF-kB/RelA which correlated with decreases in epidermal
thickness, restoration of normal markers of keratinocyte differentiation, and clinical out-
comes. These data suggest that activation of NF-kB plays a significant role in the patho-
genesis of psoriasis and that a potential mechanism of action for TNF-targeting agents is
downregulation of NF-kB transcriptional activity.
Etanercept for cicatricial pemphigoid.
M P Heffernan, D I Smith, and M J Canizares.
St. Louis, Missouri.
Cicatricial pemphigoid (CP) represents a group of autoimmune blistering diseases that can
cause scarring of the mucosal surfaces. Steroids, cyclophosphamide, and azathioprine (AZA)
are traditionally used to treat severe disease. Unfortunately, significant adverse effects fre-
quently limit the continued use of these therapies. Alternative treatments are therefore need-
ed. Enbrel is a recombinant human protein that competitively inhibits the activity of TNF-a,
which has been shown to be involved in the pathogenesis of CP. We successfully treated 2
patients with Enbrel under the hypothesis that inhibition of TNF-a activity would effectively
treat CP. The first patient is a 58 year-old female with oral CP. The patient was well controlled
on AZA 200 mg daily and Dapsone 75 mg daily, but was unable to tolerate any reduction in
her dose of AZA. Enbrel at a dose of 25 mg SC twice weekly allowed us to discontinue
Dapsone and decrease the dose of AZA to 150 mg daily. Therapy with Enbrel also led to
dramatic symptomatic improvement in her oral pain. Interestingly, the patient flared within 18
days after she discontinued taking Enbrel on her own accord. Approximately one month after
the Enbrel was resumed, she reported resolution of the flare. Her disease remains well con-
trolled 4 months later. The second patient is a 46 year-old woman with trichiasis and bilateral
symblephora from ocular CP and gingival erosions from oral CP. This patient failed treatment
with prednisone, Dapsone, and Cellcept secondary to toxic side effects. Despite treatment
with IVIG 2g/kg every 3 to 4 weeks for 13 cycles, Valtrex, and topical therapy with
cyclosporine eye drops, the patient continued to have ocular symptoms, worsening
symblephora, and recurrent herpetic ulcerations. In addition, she had persistent erosions
of her gingiva. Enbrel 25 mg SC twice weekly was initiated and the IVIG was gradually tapered
off. Four weeks later, her gingival erosions had improved and she felt a notable improvement
in her ocular symptoms, as well. Five months later, she remains free from oral involvement,
and her eyes remain stable with no further herpetic ulcerations. The pathogenesis of CP is
unclear. TNF-a has recently been implicated in the pathogenesis of CP. Here, we report the
successful treatment of 2 patients with CP with Enbrel. To our knowledge, there has only been
one report of the successful treatment of CP with Enbrel in the literature.
Medical dermatology training and practice during residency.
D. Reid, S. Salter, A. Ehrlich, and A. Kimball.
Boston, Massachusetts and Washington DC.
Dermatology residency training includes exposure to medical, surgical and cosmetic der-
matology. However, as ACGME requirements for training in surgical and cosmetic derma-
tology have increased, concern has been expressed that these changes might come at the
expense of training in medical dermatology. Several survey questions were administered to
recent residency graduates as part of a larger survey to better understand the amount of
training devoted to each of these areas as well as the amount of training in the use of
systemic therapies in clinical practice. Anonymous surveys were administered to participants
in the Galderma Board Review course in summer, 2003 in Chicago, Illinois. 180/211 (85%) of
participants returned the surveys. Residents reported spending an average of 70% of their
time in medical training, 22% in surgical training, and 7% in cosmetic training. Graduates
from programs in the Midwest reported the highest percentage of time spent in medical
dermatology (76%), followed by those from the West (72%), Northeast (69%), and South
(66%). Regional differences were statistically significant (ANOVA P¼ 0.038). Respondents
reported that on average 30% of their patients had acne, 16% had psoriasis, 7% had lupus,
6% had CTCL, and less than 5% had bullous pemphigoid or pemphigus vulgaris. Systemic
therapy was used on average in 79% of pemphigus, 78% of pemphigoid, 58% of lupus, 44%
of CTCL, 27% of psoriasis, and 19% of acne cases. No statistically significant difference in
regional use of systemic therapy was found (ANOVA 0.17oPo1.0). Dermatology residents
spend the majority (70%) of their training in medical dermatology. Although there are no
directly comparable figures, this percentage is consistent with prior data, obtained by the
AAD Resident Physician Committee between 1992–1994, showing that 67–76% of their time
was spent in medical dermatology. Graduates from programs in the Midwest spent the most
time training in medical dermatology (76%), while those from Southern programs spent the
least (66%). Trainees continue to see a substantial number of patients with significant medical
dermatologic disease and routinely treat them with systemic therapy. These results suggest
that while residency requirements for surgical and cosmetic training have increased, training
in medical dermatology is still clearly the mainstay of training in dermatology.
Mycophenolate mofetil is an effective corticosteroid-sparing therapy for recalcitrant de-
rmatomyositis.
J C Edge, J D Outland, J R Dempsey, and J P Callen.
Louisville, Kentucky.
Dermatomyositis is an inflammatory disorder that affects the skin and striated muscle. Ef-
fective therapies for the myopathy of dermatomyositis include oral corticosteroids, met-
hotrexate, azathioprine, cyclophosphamide, cyclosporin, and intravenous immune globulin.
Cutaneous disease is at times more difficult to control and therapies that have been sug-
gested include photoprotective measures, topical and/or systemic corticosteroids, topical
immune response modifiers, oral antimalarials, methotrexate and intravenous immune glob-
ulin. To evaluate the effectiveness of oral mycophenolate mofetil in patients with cutaneous
lesions of dermatomyositis recalcitrant to other therapies. We retrospectively analyzed twelve
patients with dermatomyositis treated with mycophenolate mofetil who had all failed to re-
spond to conventional therapy or had developed adverse reactions to other treatment mo-
dalities. Response was based on improvement in skin disease judged visually and
documented photographically, an increase in strength, and/or an ability to decrease or dis-
continue additional therapies, primarily corticosteroids. Improvement in skin disease and
muscle strength was seen in ten out of the twelve patients, most within 4 to 8 weeks. Most
patients tolerated MMF without problem; however one patient developed a B-cell lymphoma
of the central nervous system while on MMF and methotrexate while another had to dis-
continue MMF due to the development of lab abnormalities and urinary symptomatology. The
B-cell lymphoma spontaneously resolved upon cessation of both agents as did the laboratory
abnormalities and urinary symptoms. Mycophenolate mofetil may be an effective cortico-
steroid-sparing therapy for the treatment of some patients with dermatomyositis.
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Recalcitrant dermatomyositis responding to leﬂunomide.
J S Boswell, and M I Costner.
Metairie, Louisiana and Dallas, Texas.
Leflunomide is a novel disease-modifying antirheumatic drug (DMARD) used to treat rheu-
matoid arthritis. We present 3 patients whose recalcitrant dermatomyositis responded to
leflunomide, implicating this relatively new medicine’s promise as a treatment for rheumatic
skin disease. We describe our experience with leflunomide, and review for the dermatologist,
its mechanism of action and side effect profile. Leflunomide’s active metabolite acts as a
pyrimidine de novo synthesis inhibitor, blocking DNA and RNA synthesis in activated T cells
and B cells. Although little has been reported regarding its efficacy in skin disease, limited
studies have suggested that leflunomide might be effective in the treatment of psoriasis,
psoriatic arthritis, systemic lupus erythematosus, atopic dermatitis, and sarcoidosis. Adverse
effects commonly associated with leflunomide include nausea, vomiting, diarrhea, alopecia,
hypertension, and elevated liver enzymes. These are usually transient and respond to re-
ductions in dose.
Because of its mechanism of action and favorable risk profile, leflunomide may prove to be
both safe and effective in treating dermatomyositis and other inflammatory and/or autoim-
mune skin diseases.
Seven primary melanomas in a CDKN2A mutation carrier exposed to lonizing radiation.
M Eliason, C Hansen, K Lowsteter, P Porter-Gill, S Florell, L Swinyer, and S Leachman.
Salt Lake City, Utah.
The prevalence rate of multiple primary melanomas is estimated to be between 3%–8%, with
the rate of having three or more primary melanomas being less than 0.3%. Prior studies of
individuals with multiple primary melanomas have been useful in identifying environmental
and genetic factors that may make these individuals more susceptible to melanoma. The
investigation of patients with multiple primary melanomas is a useful means of identifying
these factors. We present a participant from our familial melanoma research clinic with a
unique environmental exposure history and nine primary melanomas, six of which occurred
on the right side of her body and three occurred midline. Her family history is significant for
one paternal cousin and one first-cousin-once removed with melanoma. She reported one
blistering sunburn before the age of 20, and an exposure to an undetermined amount of
ionizing radiation when, at the age of 23, she observed a nuclear weapons test in southern
Utah. She returned home from that test riding in the passenger seat of the car, which cor-
responded to the direction the nuclear test took place. Additional risk factors for melanoma
noted on physical examination include red hair and fair skin. She developed her first me-
lanoma at age 28 on her right ear, and then eight other primary lesions in succession over the
next 35 year on her back, arms and legs. Slides of these primary lesions were obtained and
reviewed to confirm the diagnosis of a primary melanoma. CDKN2A mutation testing revealed
a known pathogenic 50 UTR -34(G4T) germline mutation that creates an alternative start site
and frame shift. Cytogenetic evaluation did not identify additional chromosomal abnormalities
such as trisomy or mosiacism in lymphocytes or in bilaterally collected and cultured skin
fibroblasts and melanocytes. With mosaicism ruled out by cytogenetic testing, the most likely
explanation for the dramatic presentation of nine melanomas on the right side of her body
and midline is the direct effect of ionizing radiation or ultraviolet light on cells with delete-
rious CKDN2A mutations. Though no studies have been done to investigate the effects of
ionizing radiation on individuals with CDKN2A mutations, this case strongly suggests that
environmental factors can superimpose further risk upon an already genetically susceptible
individual.
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